China Healthcare: Expert call takeaways: Pulse check on China’s healthcare anti-corruption campaign

Research evidence excerpt

China Healthcare: Expert call takeaways: Pulse check on China’s healthcare anti-corruption campaign

Global Research

26 June 2026ab

China Healthcare Equities

ChinaExpert call takeaways: Pulse check on China’s

healthcare anti-corruption campaign Healthcare

Chen Chen, PhD

Analyst

chen-zb.chen@ubs.com

Key topics discussed +86-10-5832 8201

On 26 June, we hosted a seasoned domestic expert in healthcare policy for a call. The Henry Liu, CFA

discussion covered: 1) policy interpretation of the recent domestic healthcare anti- Analyst

corruption efforts and key regulatory focus; and 2) the potential impact of policy S1460520110002

updates on various sub-segments (see the replay). Overall, the expert believes that since henry-za.liu@ubs.com

2019, regulation of corruption in China’s healthcare sector has become institutionalised +86-105-832 8509

and normalised, with comprehensive coverage. The primary objective remains Anita Wei

safeguarding medical insurance funds so they can best meet patients’ basic healthcare Analyst

needs. By segment, he suggests secondary market investors focus on companies with anita.wei@ubs.com

strong technical barriers and cost-efficiency advantages, such as innovative drug firms, +852-2971 7459

especially well-funded large companies with overseas exposure. For medtech, more Jun Deng

attention should be paid to the growth potential of low-value consumables and Analyst

standard equipment. jun.deng@ubs.com

+852-3712 2103

Sustained high regulatory pressure to safeguard health insurance funds Liz Han, CFA

The expert thinks China's crackdown on healthcare corruption has become Analyst

institutionalised, normalised and comprehensive. The new judicial interpretation, liz.han@ubs.com